uploads/2018/04/Chart-03-3-1.jpg

How Analysts Rate Bristol-Myers Squibb in 1Q18

By

Updated

Wall Street analyst estimates

Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.

The above chart shows analysts’ recommendations for Bristol-Myers Squibb’s stock over the last 12 months.

Article continues below advertisement

Analysts’ ratings and recommendations

Bristol-Myers Squibb’s stock price has fallen nearly 4.8% over the last 12 months and ~16.9% in 2018 year-to-date. Analysts’ estimate that the stock price could rise ~20.5% over the next 12 months. Wall Street analysts have a 12-month targeted price of $61.35 per share as compared to the last price of $50.90 per share as of April 23, 2018.

Of the 23 analysts tracking Bristol-Myers Squibb, five analysts recommend a “strong buy,” four analysts recommend a “buy,” 11 analysts recommend a “hold,” while three analysts recommend a “sell.” The consensus rating for Bristol-Myers Squibb stands at 2.52, a moderate buy for value investors. Changes in analysts’ estimates and recommendations are based on changing trends in the stock price.

The SPDR S&P Pharmaceuticals ETF (XPH) holds 3.3% of its total investments in Bristol-Myers Squibb (BMY), 4.1% in Johnson & Johnson (JNJ), 4.3% in Eli Lilly (LLY), and 4.1% in Mylan (MYL).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

Advertisement

More From Market Realist